Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for weight loss.

Hanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press conference held in San Francisco, California, on Jan. 15. [LEE JAE-LIM] SAN FRANCISCO — Hanmi Pharmaceutical aims to disrupt the obesity drug market currently led by Eli Lilly and Novo Nordisk with its own diverse range of weight-loss treatments tailored to meet the unique needs of patients,

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.